Table 4. Incidence of cervical cancer due to HPV 16/18 in French women in each scenario 10, 20 and 50 years after initiation of vaccination (t = 0).
Time after introduction of vaccine | 10 years | 20 years | 50 years | 100 years |
Without vaccination | 9.6 | 9.6 | 9.6 | 9.6 |
Scenario 1 | 8.9 (−7.3%) | 6.5 (−32.3%) | 1.6 (−83%) | 0.5 (−94.8%) |
Scenario 2 | 8.7 (−9.4%) | 6.0 (−37.5%) | 0.8 (−91.7%) | 0.02 (−99.8%) |
Scenario 3 | 8.1 (−15.6%) | 4.8 (−50%) | 0.5 (−94.8%) | 0.05 (−99.5%) |
Scenario 4 | 7.9 (−17.7%) | 4.2 (−56.3%) | 0.2 (−97.9%) | <10−5 (−100%) |
Scenario 5 | 8.5 (−11.5%) | 5.3 (−44.8%) | 0.7 (−92.7%) | 0.07 (−99.3%) |
Vaccine coverage was supposed constant in each scenario. In parentheses, % of reduction in cervical cancer incidence compared to the case without vaccination.